VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

Bayer

Status: Completed

Conditions: Chronic Bronchitis; Disease Exacerbation

Treatments: Drug: Moxifloxacin (Avelox, BAY12-8039)

Study type: Observational

Funder types: Industry

Identifiers

NCT00876577

AX0810CN (Other Identifier)

14495

Details and patient eligibility

About

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely prescribed. The secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different treatment effectiveness according to Anthonisen classification. This study will also collect the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection in treating Acute Exacerbations of Chronic Bronchitis (AECB).

Enrollment: 1,206 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients at least 18 years of age with a diagnosis of AECB treated with Moxifloxacin injection with/without sequential tablet treatment

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information

Trial design

1,206 participants in 1 patient group

Group 1

Treatment:

Drug: Moxifloxacin (Avelox, BAY12-8039)